IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

June 30, 2016

Conditions
Myocardial InfarctHeart Failure
Interventions
PROCEDURE

Injection of stem cells at time of coronary artery bypass grafting

Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.

Trial Locations (1)

H2W 1T8

Centre de recherche du CHUM (CRCHUM), Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Miltenyi Biotec, Inc.

INDUSTRY

collaborator

Centre de Recherche du Centre Hospitalier de l'Université de Montréal

OTHER

collaborator

Maisonneuve-Rosemont Hospital

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER